Bruton tyrosine kinase inhibitor in B cell malignancies
10.3760/cma.j.issn.1009-9921.2013.08.018
- VernacularTitle:Bruton酪氨酸激酶抑制剂在B细胞恶性肿瘤中的研究进展
- Author:
Guangzhong YANG
;
Chuanying GENG
- Publication Type:Journal Article
- Keywords:
Bruton tyrosine kinase;
Inhibitor;
B cell malignancy
- From:
Journal of Leukemia & Lymphoma
2013;22(8):504-506
- CountryChina
- Language:Chinese
-
Abstract:
Bruton tyrosine kinase (BTK) is a non-receptor tyrosine kinase which belongs to the Tec kinase family and plays an important role in B cell receptor signaling.Nowadays,BTK has been a nove] target for treating some B cell malignancies.Recently,some studies have confirmed that BTK inhibitor,PCI-32765 (ibrutinib),can effectively treat chronic lymphocytic leukemia,mantle cell lymphoma and so on.This review will discuss the preclinical and clinical development of this BTK inhibitor in B cell malignancies.
